Demographics (3)
- AGE - Age at immunotherapy treatment start (phv00534394.v1.p1)
- SEX - Sex at birth (phv00534391.v1.p1)
- SEX - Biological sex (phv00534385.v1.p1)
Race and Ethnicity (2)
- ETHNICITY - Self reported ethnicity (phv00534393.v1.p1)
- RACE - Self reported race (phv00534392.v1.p1)
Substance Use (2)
- PACK_YRS - Self reported pack years (phv00534396.v1.p1)
- SMOKING - Self reported smoking status (phv00534395.v1.p1)
Other (20)
- ANALYTE_TYPE - Analyte Type (phv00534406.v1.p1)
- BOR - Best overall treatment response by RECIST 1.1 (phv00534400.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00534384.v1.p1)
- GEO_ACCESSION - GEO accession ID (GSM#) (phv00534389.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00534408.v1.p1)
- IO_REGIMEN - Immunotherapy drug regimen (phv00534397.v1.p1)
- IS_TUMOR - Tumor status (phv00534407.v1.p1)
- OS - Overall survival from treatment start in months (phv00534403.v1.p1)
- OS_CENSOR - Overall survival cenor (phv00534404.v1.p1)
- PFS - Progression free survival from treatment start in months (phv00534401.v1.p1)
- PFS_CENSOR - Progression free survival censor (phv00534402.v1.p1)
- PRIOR_TX - Therapies received before immunotherapy (phv00534398.v1.p1)
- SAMPLE_ID - Sample ID (phv00534405.v1.p1)
- SAMPLE_ID - Sample ID (phv00534387.v1.p1)
- SUBJECT_ID - Subject ID (phv00534390.v1.p1)
- SUBJECT_ID - Subject ID (phv00534383.v1.p1)
- SUBJECT_ID - Subject ID (phv00534386.v1.p1)
- SUBJECT_ID - Subject ID (phv00536066.v1.p1)
- TOT - Time on immunotherapy treatment in months (phv00534399.v1.p1)
- TUMOR_TREATMENT - Immunotherapy timing relative to sample (phv00534409.v1.p1)